Intraarterially administered XXXX as adjunct therapy for @entity2553 : safety and 2-year experience.

@entity1 @entity428 @entity510 @entity1855 @entity2553
BACKGROUND AND PURPOSE: Despite the widespread use of angioplasty, adjunct chemical therapy is often needed to treat @entity1 with @entity2553 . In this study, we examined the safety of intraarterial administration of @entity1855 to @entity1 with @entity2553 . We herein summarize our 2-year experience with this treatment. METHODS: We retrospectively reviewed the procedure reports, anesthesia records, clinical charts, and brain images of 29 @entity1 who received intraarterially administered @entity1855 in 34 procedures for the treatment of @entity2553 after @entity510 from July 1998 to June 2000. The average changes in mean arterial pressure and heart rate were used to measure cardiovascular side effects. The neurologic effects were assessed by angiographic findings, the results of neurologic examinations performed before and after the procedure, and findings of CT of the head. RESULTS: The average dose of @entity1855 per @entity1 was 3 +/- 0 mg or 44 +/- 5 mcg/kg. The average changes in mean arterial pressure at 10 and 20 minutes were -5 +/- 1 mm Hg and -2 +/- 1 mm Hg or -3.8 +/- 1.0% and -1.7 +/- 1.1%, respectively. No significant change of heart rate was observed at 10 minutes. The @entity1 showed no sign of @entity428 by hemodynamic parameters, neurologic examination, or CT of the head. On 10 occasions, when the effect of @entity1855 infusion was assessed angiographically, there was 44 +/- 9% increase of vessel diameter in the spastic segment. Neurologic improvement was noted after five of 17 procedures when @entity1855 was used as the sole treatment. CONCLUSION: Low dose @entity1855 is safe when administered intraarterially to @entity1 with @entity2553 . Beneficial effects are achieved in some @entity1 , prompting further study of its efficacy.
